A direct salesforce is employed and trained by the manufacturer. Distributors are independent firms that carry the product alongside others. Hybrid models - direct in core geographies, distributors in long tail or OUS - are common. Distributors offer faster market access and local relationships, while direct sales give more control and margin. Many companies use distributors in smaller markets and sell directly in large ones. Contracts should cover exclusivity, complaint handling, vigilance duties and termination rights.

Why it matters

Direct gives control of brand, KOL, and pricing; costs more upfront. Distributors give faster geographic reach with weaker control. Most MedTech companies start hybrid and convert to direct as scale justifies.

Common pitfalls

•Manufacturers often incorrectly assume that distributors completely absorb regulatory responsibilities, leading to gaps in compliance oversight.
•Failing to establish clear contractual agreements with distributors regarding regulatory responsibilities, post-market surveillance, and incident reporting can lead to significant issues.
•Not adequately training distributors on product use, regulatory requirements, and quality system procedures is a common mistake.
•Assuming that direct sales models eliminate all regulatory risks associated with external sales channels overlooks internal training and oversight needs.
•Neglecting to monitor distributor performance and adherence to quality agreements can result in non-compliance and reputational damage.

Sources

AdvaMed commercialization · AdvaMed
AHRMM - Healthcare Supply Chain · AHRMM
AdvaMed Code of Ethics · AdvaMed
FDA registration and listing: commercial distribution (regulatory context) · U.S. Food and Drug Administration

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.